Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00621842
Other study ID # L0971
Secondary ID GSK110720IND 78,
Status Completed
Phase Phase 3
First received February 12, 2008
Last updated December 8, 2014
Start date January 2008
Est. completion date March 2010

Study information

Verified date December 2014
Source University Hospital Case Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a 12-week, open label trial of lamotrigine for older adults (age 60 and older) with type I or type II Bipolar depression. Non-demented older adults with Bipolar I or II depression, confirmed via the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (DSM) - Patient edition (SCID-I/P) and meeting inclusion criteria for depressive symptom severity (score of 18 or greater on the Hamilton Depression Rating Scale/HAM-D-24) will receive add-on lamotrigine dosed to a target of 200 mg/day.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 60 Years and older
Eligibility Inclusion Criteria:

- Age 60 Years or older

- BP Disorder-I or II: Depressive episode (DSM -IV-TR; SCID-I/P)

- HAM-D score > 18 (GRID-HAM-D 24-item version)

- Availability of an Informant is encouraged but not required for study participation

Exclusion Criteria:

- Chronic psychotic conditions, ie. schizophrenia, schizoaffective disorder, delusional disorder

- Contraindication to lamotrigine (Physician interview, medical assessment)

- Documented history of intolerance to lamotrigine

- Patients who have previously failed to respond to at least 12 weeks of treatment with lamotrigine

- Active substance dependence (SCID-I/P) or substance-related safety issues or PI concerns

- Mood Disorder Due to a General Medical Condition or Treatment (Physician interview)

- Rapid cycling (Physician interview): As defined in DSM-IV: At least 4 episodes of mood disturbance in the previous 12 months that meet criteria for a Major Depressive, Manic, Mixed or Hypomanic Episode. Episodes are distinguished either by partial or full remission for at least 2 months or by a switch to an episode of opposite polarity

- Dementia (by DSM-IV or brain degenerative diseases; Physician interview);

- Inability to communicate in English (i.e., interview cannot be conducted without an interpreter; subject largely unable to understand questions and cannot respond in English)

- Clinically significant sensory impairment (i.e., cannot see well enough to read consent or visually-presented material; cannot hear well enough to cooperate with interview; Physician interview)

- Recent history of cardiovascular, peripheral vascular events or stroke

- High risk for suicide (e.g., active SI or current intent or plan)

- Inpatient status

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Lamotrigine regular tablet formulation
Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
Lamotrigine novel formulation
Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used. Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.

Locations

Country Name City State
United States University Hospitals Case Medical Center/ Case Western Reserve University Cleveland Ohio
United States Baylor College of Medicine/Michael E. DeBakey VAMC Houston Texas
United States University of Pennsylvania Philadelphia Pennsylvania
United States University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic Pittsburgh Pennsylvania
United States Weill Medical College of Cornell University White Plains New York

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Case Medical Center GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of Change in Depressive Symptoms From Baseline on the Montgomery Asberg Depression Rating Scale (MADRS) The minimum possible score is 0 and the maximum score is 60. A higher score implies a worse condition. 12 weeks No
Secondary Assessment of Adverse Effects With the Udvalg Fur Kliniske Undersogelser (UKU) Frequency of adverse effects was measured using the UKU. The total number of adverse effects assessed by the UKU is 49 plus one open-ended question about any adverse effects not assessed. 12 weeks Yes
Secondary Change in Depressive Symptoms From Baseline Using the Hamilton Depression Rating Scale (GRID-HAM-D) The minimum possible score is 0 and the maximum score is 78. A higher score implies a worse condition. 12 weeks No
Secondary Change in Manic Symptoms From Baseline Using the Young Mania Rating Scale (YMRS) The minimum possible score is 0 and the maximum score is 60. A higher score implies a worse condition. 12 weeks No
Secondary Change From Baseline in Overall Clinical Diagnosis Using the CGI-BP The minimum possible score is 1 and the maximum score is 7. A higher score implies a worse condition. 12 weeks No
Secondary Change in or Appearance of Extrapyramidal Symptoms From Baseline Using the Simpson Angus Scale (SAS) The minimum possible score is 0 and the maximum score is 4. A higher score implies a worse condition. 12 weeks No
Secondary Change in Body Weight From Baseline 12 weeks No
Secondary Number of Participants Who Fell at Least Once During the Study 12 weeks Yes
Secondary Change in Appearance of Extrapyramidal Symptoms From Baseline Using the Abnormal Involuntary Movement Scale (AIMS) The minimum possible score is 0 and the maximum score is 4. A higher score implies a worse condition. 12 weeks No
Secondary Change in or Appearance of Extrapyramidal Symptoms From Baseline Using the Barnes Akathisia Scale (BAS) The minimum possible score is 0 and the maximum score is 5. A higher score implies a worse condition. 12 weeks No
Secondary Number of Participants Who Had a Fall That Required Medical Attention 12 weeks Yes
Secondary Number of Participants Who Had a Fall That Required Medical Attention and Was Related to Lamotrigine 12 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2